一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (694k)
Article in Japanese

Case Report

Three cases of panitumumab-induced interstitial lung disease

Megumi Inadaa  Tomoya Shimokataa  Mihoko Sugishitaa  Yoshinori Hasegawab  Yuichi Andoa 

aDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital
bDepartment of Respiratory Medicine, Nagoya University Hospital

ABSTRACT

Panitumumab, a fully-human monoclonal antibody against epidermal growth factor receptor (EGFR), is used as standard chemotherapy for patients with advanced colorectal cancer. From June 2010 to April 2011, 3 of 13 patients who received panitumumab-containing chemotherapy in our hospital developed interstitial lung disease (ILD); in all 3 we suspected a causal relationship between panitumumab and the ILD. The 3 had multiple lung metastases; 2 had a smoking history; and 1 had signs of suggestive unspecified interstitial change on a CT scan at the beginning of the panitumumab therapy. The ILD was diagnosed 54, 15, and 15 days after initiation of the panitumumab therapy, respectively. The first patient died 22 days after the diagnosis of ILD, and the second and third recovered and remain alive. The first and second patients received steroid pulse therapy after discontinuation of the drug, and the third recovered without steroid therapy. The frequency and clinical features of panitumumab-associated ILD remain to be elucidated. However, since gefitinib and erlotinib, which also target EGFR may cause serious ILD, careful monitoring of ILD is necessary in patients who receive panitumumab therapy.

KEYWORDS

Panitumumab  Interstitial lung disease  Anti-epidermal growth factor receptor antibody 

Received 6 Jun 2011 / Accepted 31 Aug 2011

AJRS, 1(1): 46-50, 2012

Google Scholar